Silence Therapeutics (SLN) Capital Expenditures (2020 - 2025)
Silence Therapeutics recorded quarterly Capital Expenditures of $3000.0 in Q3 2025, down 93.75% quarter-over-quarter from $48000.0 in Q2 2025, and up 104.71% year-over-year from $1465.5 in Q3 2024.
Silence Therapeutics' Capital Expenditures history runs 6 years deep, the most recent figure standing at $3000.0 for Q3 2025.
- In Q3 2025, Capital Expenditures rose 104.71% year-over-year to $3000.0; the TTM figure through Mar 2026 stood at $51000.0 (down 41.6% YoY), while the FY2025 annual figure was $55000.0, down 73.93% from the prior year.
- Capital Expenditures came in at $3000.0 for Q3 2025 at Silence Therapeutics, down from $48000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $2.8 million in Q4 2021 to a low of -$613602.7 in Q2 2021.
- A 5-year average of $115614.4 and a median of -$8152.4 in 2021 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures plunged 1437.36% in 2021 and soared 2164.2% in 2024, its largest moves.
- Silence Therapeutics' Capital Expenditures stood at $2.8 million in 2021, then tumbled by 88.5% to $324901.1 in 2022, then tumbled by 66.0% to $110462.5 in 2023, then slumped by 43.87% to $62000.0 in 2024, then tumbled by 95.16% to $3000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $3000.0, $48000.0, and $4000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 48,000.00 |
| Jun 30, 2025 | 48,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 62,000.00 |
| Dec 31, 2024 | 62,000.00 |
| Sep 30, 2024 | -63,665.71 |
| Sep 30, 2024 | -63,665.71 |
| Jun 30, 2024 | 85,000.00 |
| Jun 30, 2024 | 85,000.00 |
| Dec 31, 2023 | 110,462.52 |
| Dec 31, 2023 | 110,462.52 |
| Sep 30, 2023 | -25,333.70 |
| Sep 30, 2023 | -25,333.70 |
| Jun 30, 2023 | 3,754.09 |
| Jun 30, 2023 | 3,754.09 |
| Mar 31, 2023 | -32,818.76 |
| Mar 31, 2023 | -32,818.76 |
| Dec 31, 2022 | 324,901.14 |
| Dec 31, 2022 | 324,901.14 |
| Sep 30, 2022 | -55,391.77 |
| Sep 30, 2022 | -55,391.77 |
| Jun 30, 2022 | -46,594.63 |
| Jun 30, 2022 | -46,594.63 |
| Mar 31, 2022 | -71,117.29 |
| Mar 31, 2022 | -71,117.29 |
| Dec 31, 2021 | 2.82 Mn |
| Dec 31, 2021 | 2.82 Mn |
| Sep 30, 2021 | -456,311.09 |
| Sep 30, 2021 | -456,311.09 |
| Jun 30, 2021 | -613,602.70 |
| Jun 30, 2021 | -613,602.70 |
| Mar 31, 2021 | -19,304.89 |
| Mar 31, 2021 | -19,304.89 |
| Dec 31, 2020 | 1.23 Mn |
| Dec 31, 2020 | 1.23 Mn |
| Sep 30, 2020 | -29,681.56 |
| Sep 30, 2020 | -29,681.56 |